Halozyme Therapeutics Inc

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ 1777.13, 2000.88, 2183.78, 1932.5, 1786.45 ], "ebit_estimate": [ 1018.48, 1297.2, 1437.52, 1208.73, 1023.65 ], "ebitda_estimate": [ 1143.91, 1400.91, 1553.29, 1485, 1307.9 ], "net_income_estimate": [ 959.48, 1148.56, 1263.78, 1123.8, 969.95 ], "per_share_eps_estimate": [ 6.7, 9.12, 9.81, 9.03, 7.69 ], "eps_nri_estimate": [ 8.14, 9.89, 10.87, 9.63, 8.65 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ 6.36, 15.12, 25.16, null, null ], "pretax_income_estimate": [ 1067.59, 1355.7, 1544.89, 1293, null ], "operating_cash_flow_per_share_estimate": [ 8.02, 10.95, 12.54, null, null ], "roa_estimate": [ 34.8, 32.5, 28.4, null, null ], "roe_estimate": [ 232.24, 88.85, 52.97, null, null ], "gross_margin_estimate": [ 61.53, 70.67, 64.55, 44, 45 ], "operating_cash_flow_estimate": [ 985.46, 1345.48, 1540.85, null, null ], "pettm_estimate": [ 11.38, 8.35, 7.77, 8.44, 9.91 ], "long_term_growth_rate_mean": 36.1, "long_term_revenue_growth_rate_mean": "15.72", "future_per_share_eps_estimate_growth": 54.32, "future_eps_nri_estimate_growth": 36.1, "future_revenue_estimate_growth": 15.72, "future_ebit_estimate_growth": 43.36, "future_ebitda_estimate_growth": 32.06, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": 33.71, "future_pretax_income_estimate_growth": 46.65, "future_book_value_per_share_estimate_growth": 273.86, "future_roa_estimate_growth": null, "future_roe_estimate_growth": -42.76, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": 33.96 }

{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712" ], "revenue_estimate": [ 403.98, 464.96, 528.97, 461.95, 494.85, 501.9, 536.45 ], "ebit_estimate": [ 232.13, 281.83, 336.74, 282.65, 313.85, 319.46, 353.67 ], "ebitda_estimate": [ 254.79, 317.95, 378.59, 322.71, 338.01, 356.14, 408.4 ], "net_income_estimate": [ 214.83, 250.93, 293.95, 256, 293, 288, 301 ], "per_share_eps_estimate": [ 1.5, 1.84, 2.13, 2.15, 2.31, 2.49, 2.96 ], "eps_nri_estimate": [ 1.82, 2.18, 2.55, 2.26, 2.49, 2.55, 2.62 ], "dividend_estimate": [ null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null, null, null ], "pretax_income_estimate": [ 249.2, 293, 348.3, 300.44, 319.27, 341.16, 401.64 ], "operating_cash_flow_per_share_estimate": [ 1.82, 2.1, 2.46, null, null, null, null ], "roa_estimate": [ null, null, null, null, null, null, null ], "roe_estimate": [ null, null, null, null, null, null, null ], "gross_margin_estimate": [ 39.75, 40, 40.25, null, null, null, null ], "operating_cash_flow_estimate": [ 223.63, 258.04, 302.27, null, null, null, null ], "pettm_estimate": [ 10, 9.04, 8.39, 7.69, null, null, null ], "long_term_growth_rate_mean": 36.1, "long_term_revenue_growth_rate_mean": "15.72", "future_per_share_eps_estimate_growth": 54.32, "future_eps_nri_estimate_growth": 36.1, "future_revenue_estimate_growth": 15.72, "future_ebit_estimate_growth": 43.36, "future_ebitda_estimate_growth": 32.06, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": 33.71, "future_pretax_income_estimate_growth": 46.65, "future_book_value_per_share_estimate_growth": 273.86, "future_roa_estimate_growth": null, "future_roe_estimate_growth": -42.76, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": 33.96 }